Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bill Ackman’s Latest Herbalife Move Doesn’t Make Any Sense: Wall Street Pro

D.A. Davidson analyst, Herbalife, Bill Ackman: About an hour ago, MarketWatch’s the Tell reported that D.A. Davidson analyst Tim Ramey had a few words for Bill Ackman and his Herbalife (NYSE:HLF) short. The entire Pershing Square 2013 Q3 Investor Letter is uploaded on Insider Monkey, and in it, Ackman describes how he’s replacing about 40% of his short position with long-term puts on the company.

Regarding D.A. Davidson’s Tim Ramey, MarketWatch shared that he had this to say about Ackman:

“I would take my record on Herbalife versus Bill Ackman’s Herbalife record hands down.”

We’ve obtained a full copy of D.A. Davidson’s new report on Herbalife that holds a price target of $92 on the stock for the next 12-18 months; shares are currently near $69. D.A. Davidson’s five-year price target amounts to $120 a share.

One interesting aspect of the report is that it discusses what type of put options Ackman likely bought: out-of-the-money puts.

Bill Ackman in crowd

Here’s Tim Ramey’s thoughts on the move:

“Pershing likely bought out-of- the-money (e.g., $37.50 strike price, at half HLF’s current price) puts covering 10 million shares (100,000 puts if conventional 100 multiplier of listed puts) from a very lucky counterparty. We say lucky because it is highly likely that these puts will expire worthless and Pershing’s counterparty will get to pocket the price of the puts at a time when the implied volatility is at historically unprecedented levels.”

On the subject of Ackman’s reasoning behind the move, Ramey said that the “new bearish position seems at odds with Pershing Square’s goals,” adding, “If it truly still believes the go-to-zero thesis […] then it makes no sense to put a time element into this trade.”

Lastly, perhaps what investors would like to know the most, Ramey shares his thoughts on how the market may trade Herbalife after the Pershing letter. His thoughts on that:

“Clearly there is capitulation in these actions and that may well send Herbalife shares much higher – and there is the small matter of the remaining ~ 14.5 million shares that are sold-short by Pershing. We would anticipate that the volume will be huge in the next five trading sessions and the stock may very move much higher. We reiterate our BUY rating and $92 price target.”

Recommended reading:

Pershing Square 2013 Q3 Investor Letter

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!